Clinical trial
Efficacy and Safety of Growth Hormone Treatment in Juvenile Idiopathic Arthritis
NCT00420251 · Ludwig-Maximilians - University of Munich, Other · Completed
Key facts
| NCT number | NCT00420251 |
|---|---|
| Title | Efficacy and Safety of Growth Hormone Treatment in Juvenile Idiopathic Arthritis |
| Official title | Recombinant Human Growth Hormone Treatment in Juvenile Idiopathic Arthritis: Controlled Study on the Effect on Growth and Bone Development |
| Lead sponsor | Ludwig-Maximilians - University of Munich, Other |
| Collaborators | Pfizer Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Juvenile Idiopathic Arthritis, Still Disease, Juvenile-Onset |
| Intervention type | Drug |
| Interventions | Genotropin |
| Enrollment | 50 |
| Start date | Mar 1, 1996 |
| Completion | Jul 1, 2006 |
| First posted | Jan 11, 2007 |
| Last update posted | Jan 11, 2007 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: